{"title":"抑制trna作为无义突变相关病理的个性化治疗","authors":"Zoya Ignatova, Suki Albers","doi":"10.1016/j.pharmthera.2025.108919","DOIUrl":null,"url":null,"abstract":"<div><div>Nonsense mutations – associated with many devastating genetic disorders that currently lack effective treatments – prematurely terminate protein synthesis by converting an amino acid-encoding sense codon into a termination codon. Transfer RNAs (tRNAs), essential players in protein synthesis, have naturally evolved to decode sense codons, while avoiding the three stop codons (UGA, UAG, and UAA) that signal termination of translation. Emerging therapeutic strategies increasingly focus on refactoring natural tRNAs into suppressor tRNAs (sup-tRNAs). These engineered sup-tRNAs recognize nonsense mutation-associated premature stop codons (PTCs), restore translation, and recover protein function. This review summarizes recent advances in the design of sup-tRNAs to decode PTCs and discusses critical milestones in developing sup-tRNAs as a personalized therapeutic approach tailored to individual genetic backgrounds for treating pathologic conditions associated with nonsense mutations.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"274 ","pages":"Article 108919"},"PeriodicalIF":12.5000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies\",\"authors\":\"Zoya Ignatova, Suki Albers\",\"doi\":\"10.1016/j.pharmthera.2025.108919\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Nonsense mutations – associated with many devastating genetic disorders that currently lack effective treatments – prematurely terminate protein synthesis by converting an amino acid-encoding sense codon into a termination codon. Transfer RNAs (tRNAs), essential players in protein synthesis, have naturally evolved to decode sense codons, while avoiding the three stop codons (UGA, UAG, and UAA) that signal termination of translation. Emerging therapeutic strategies increasingly focus on refactoring natural tRNAs into suppressor tRNAs (sup-tRNAs). These engineered sup-tRNAs recognize nonsense mutation-associated premature stop codons (PTCs), restore translation, and recover protein function. This review summarizes recent advances in the design of sup-tRNAs to decode PTCs and discusses critical milestones in developing sup-tRNAs as a personalized therapeutic approach tailored to individual genetic backgrounds for treating pathologic conditions associated with nonsense mutations.</div></div>\",\"PeriodicalId\":402,\"journal\":{\"name\":\"Pharmacology & Therapeutics\",\"volume\":\"274 \",\"pages\":\"Article 108919\"},\"PeriodicalIF\":12.5000,\"publicationDate\":\"2025-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0163725825001317\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163725825001317","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Suppressor tRNAs as personalized therapy for nonsense mutation-associated pathologies
Nonsense mutations – associated with many devastating genetic disorders that currently lack effective treatments – prematurely terminate protein synthesis by converting an amino acid-encoding sense codon into a termination codon. Transfer RNAs (tRNAs), essential players in protein synthesis, have naturally evolved to decode sense codons, while avoiding the three stop codons (UGA, UAG, and UAA) that signal termination of translation. Emerging therapeutic strategies increasingly focus on refactoring natural tRNAs into suppressor tRNAs (sup-tRNAs). These engineered sup-tRNAs recognize nonsense mutation-associated premature stop codons (PTCs), restore translation, and recover protein function. This review summarizes recent advances in the design of sup-tRNAs to decode PTCs and discusses critical milestones in developing sup-tRNAs as a personalized therapeutic approach tailored to individual genetic backgrounds for treating pathologic conditions associated with nonsense mutations.
期刊介绍:
Pharmacology & Therapeutics, in its 20th year, delivers lucid, critical, and authoritative reviews on current pharmacological topics.Articles, commissioned by the editor, follow specific author instructions.This journal maintains its scientific excellence and ranks among the top 10 most cited journals in pharmacology.